Novo Nordisk headquarters building in Denmark, featuring a modern, curved glass and white-panel facade with a prominent blue sign displaying the company logo in the foreground. Novo Nordisk headquarters. Courtesy of News Øresund - Johan Wessman - Licensed under CC BY 3.0. Photo link: https://www.flickr.com/photos/newsoresund/29190030262.

​Novo Nordisk has entered a $2B licensing deal for UBT251, an experimental triple-agonist drug targeting obesity and type 2 diabetes, positioning it as a potential competitor to Lilly's retatrutide.

jcst2d.com/index.php?vi...

#NovoNordisk #UBT251 #TripleAgonist #ObesityTreatment #BiotechLicensing